

	Type	L #	Hits	Search Text	Dbs	Time Stamp	Comments	Error Definition	Error Rows
1	BRS	L1	517	(glucagon-like adj peptide) or glp-1 or glp-2	USPAT; US-PGPUB; EPO; DERWENT	2002/05/27 13:58			0
2	BRS	L2	25206	liposome	USPAT; US-PGPUB; EPO; DERWENT	2002/05/27 13:59			0
3	BRS	L3	14	1 same 2	USPAT; US-PGPUB; EPO; DERWENT	2002/05/27 14:04			0
4	BRS	L4	6	1 same conjugate	USPAT; US-PGPUB; EPO; DERWENT	2002/05/27 14:04			0

	Type	L #	Hits	Search Text	DBs	Time Stamp	Comments	Error Definition	Errors
1	BRS	L1	517	(glucagon-like adj peptide) or glp-1 or glp-2	USPAT; US-PGPUB; EPO; DERWENT	2002/05/27 20:14			0
2	BRS	L2	182	1 same analog	USPAT; US-PGPUB; EPO; DERWENT	2002/05/27 20:15			0
3	BRS	L3	100	1 same fragment	USPAT; US-PGPUB; EPO; DERWENT	2002/05/27 20:15			0

Glucagons and Glucagon-Like Peptides

<p>-15 °C</p> <p>Glucagon (1-29) (human, bovine, porcine)</p> <p>H-His-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Ser-Arg-Arg-Ala-Gln-Asp-Phe-Vol-Gln-Trp-Leu-Met-Asn-Thr-OH</p> <p>$C_{13}H_{22}N_4O_{15}$ M_r: 3482.80 [16941-32-5]</p>	<p>H-6790.0500</p> <p>0.5 mg</p> <p>180.-</p> <p>320.-</p>
<p>-15 °C</p> <p>(Des-His¹ Glu²)-Glucagon (1-29) amide (human, bovine, porcine)</p> <p>H-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Glu-Tyr-Ser-Lys-Tyr-Leu-Asp-Ser-Arg-Arg-Ala-Gln-Asp-Phe-Vol-Gln-Trp-Leu-Met-Asn-Thr-NH₂</p> <p>$C_{14}H_{22}N_4O_{15}$ M_r: 3358.70 [110084-95-2]</p> <p>Glucagon antagonist.</p> <p>Lit. C.G.Unson et al., <i>Peptides</i> 10, 1171 (1989)</p>	<p>H-2754.0500</p> <p>H-2754.1000</p> <p>0.5 mg</p> <p>1 mg</p> <p>135.-</p> <p>200.-</p>
<p>-15 °C</p> <p>Glucagon (1-37) (porcine)</p> <p>H-His-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Ser-Arg-Arg-Ala-Gln-Asp-Phe-Vol-Gln-Trp-Leu-Met-Asn-Thr-Lys-Arg-Asn-Lys-Asn-Asn-Ile-Ala-OH</p> <p>(Oxytomodulin (porcine))</p> <p>Lit. D.Boraille et al., <i>Peptides</i> 2 (suppl. 2), 41 (1981) / D.Boraille et al., <i>Ann. N.Y. Acad. Sci.</i> 527, 168 (1988)</p>	<p>H-6880.0500</p> <p>H-6880.1000</p> <p>0.5 mg</p> <p>1 mg</p> <p>430.-</p> <p>785.-</p>
<p>-15 °C</p> <p>Glucagon (19-29) (human, bovine, porcine)</p> <p>H-Ala-Gln-Asp-Phe-Vol-Gln-Trp-Leu-Met-Asn-Thr-OH</p> <p>$C_{41}H_{69}N_{13}O_{18}$ M_r: 1352.53 [64790-15-4]</p> <p>This glucagon fragment inhibited both the Ca^{2+} activated and Mg^{2+} dependent ATPase activity and Ca^{2+} transport in liver plasma membranes with an efficiency 1000-fold higher than that of glucagon. It is likely to be the active peptide involved in the inhibition of the liver Ca^{2+} pump.</p> <p>Lit. A.Mollat et al., <i>Nature</i> 325, 620 (1987)</p>	<p>H-2758.0001</p> <p>H-2758.0005</p> <p>1 mg</p> <p>5 mg</p> <p>35.-</p> <p>145.-</p>
<p>-15 °C</p> <p>Glucagon-Like Peptide 1 amide (human)</p> <p>H-His-Asp-Glu-Phe-Glu-Arg-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Vol-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Vol-Lys-Gly-Arg-NH₂</p> <p>(GLP-1 amide (human); Preproglucagon (72-107) amide (human))</p> <p>$C_{142}H_{227}N_{45}O_{187}$ M_r: 4111.50 [99658-04-5]</p> <p>Lit. D.J.Drucker et al., <i>Proc. Natl. Acad. Sci. USA</i> 84, 3434 (1987) / J.J.Holst et al., <i>FEBS Lett.</i> 211, 169 (1987)</p>	<p>H-6025.0500</p> <p>H-6025.1000</p> <p>0.5 mg</p> <p>1 mg</p> <p>215.-</p> <p>395.-</p>

-15 °C

Glucagon-Like Peptide 1 (7-36) amide (human)

H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Vol-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Vol-Lys-Gly-Arg-NH₂

(GLP-1 (7-36) amide (human); Preproglucagon (78-107) amide (human))

$C_{142}H_{226}N_{45}O_{186}$ M_r : 3297.68 [107444-51-9]

This GLP-1 fragment is secreted from the lower small intestine and shows a strong insulinotropic effect. It is presently considered as the most important incretin hormone. Its action is mediated by receptors expressed by the endocrine pancreatic B-cells.

Lit. B.Kaymann et al., *Lancet* **1987** *ii*, 1300 / G.I.Bell et al., *Nature* **304**, 368 (1983) / C.Ostkov and J.H.Nielsen, *FEBS Lett.* **229**, 175 (1988) / J.P.Raufman et al., *J. Biol. Chem.* **267**, 21432 (1992) / P.A.Martin and A.Faulker, *Comp. Biochem. Biophys.* **105A**, 705 (1993) / H.C.Fehmman et al., *Peptides* **15**, 453 (1994) / M.A.Nauck et al., *Exp. Clin. Endocrinol. Diabetes* **105**, 187 (1997)

-15 °C

new (Ser⁷)-Glucagon-Like Peptide 1 (7-36) amide (human)

H-His-Ser-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Vol-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Vol-Lys-Gly-Arg-NH₂

((Ser⁷)-GLP-1 (7-36) amide (human); (Ser⁷)-Prepro-glucagon (78-107) amide (human))

The replacement of alanine by serine significantly improved the plasma stability of GLP-1 (7-36) amide against DPP IV without impairing its insulinotropic activity. This may indicate that this modification could improve the potential of GLP-1 in the treatment of type-II diabetes.

Lit. U.Ritzel et al., *J. Endocrinol.* **159**, 93 (1998)

-15 °C

new Glucagon-Like Peptide 2 (human)

H-His-Ala-Asp-Gly-Ser-Phe-Ser-Asp-Glu-Met-Asn-Thr-Ile-Leu-Asp-Asn-Leu-Ala-Ala-Arg-Arg-Phe-Ile-Asn-Trp-Leu-Gln-Thr-Lys-Ile-Thr-Asp-Arg-OH

(GLP-2 (human); Preproglucagon (126-159) (human))

$C_{171}H_{246}N_{46}O_{185}$ M_r : 3922.35

Like GLP-1, GLP-2 is secreted from enteroendocrine cells in a nutrient-dependent manner in both rodents and humans. Currently GLP-2 is used as a potential therapeutic agent for human subjects with a broad variety of intestinal diseases characterized by intestinal damage and insufficiency.

Lit. D.J.Drucker, *Trends Endocrinol. Metab.* **10**, 153 (1999) / D.J.Drucker et al., *J. Parenter. Enterol Nutr.* **23**, 598 (1999)

-15 °C

D-Gluconyl-Vol-Leu-Gly-Lys-NHEt

$C_{27}H_{51}N_5O_{16}$ M_r : 620.74 [121459-49-2]

Inhibitor of the Plasmadomium folcipurum proteinase (K_i = 480 μM) and of the erythrocyte invasion by Plasmadomium folcipurum merozoitis (IC₅₀ = 900 μM).

Lit. R.Mayer et al., *J. Med. Chem.* **34**, 3029 (1991)

-15 °C

Glucose-Dependent Insulinotropic Polypeptide (human)

(See Gastric Inhibitory Polypeptides and Fragments Page 415)

(H-Glu(Cys-βNA)-OH)₂

(H-γ-Glu-Cys-βNA)₂

$C_{64}H_{106}N_8O_{52}$ M_r : 748.88